| abstract |
FIELD: chemistry. n SUBSTANCE: invention relates to a pharmaceutical composition containing primary material in form of at least one compound selected from 5-[(1'R)-1'-[(1aS,3aS,4S,7R,7aR,7bS)-decahydro-7-hydroxy-1,1,3a , 7-tetramethyl-1H-cyclopropa[A]naphthalen-4-yl]-3'-methylbutyl]-2,4,6-trihydroxy-1,3-benzene dicarboxaldehyde and 5-[(1'S)-1'-[(1aS,3aS,4S,7R,7aR,7bS)-decahydro-7-hydroxy-1,1,3a,7-tetramethyl-1H-cyclopropa[A]naphthalen-4-yl]-3 ' -methylbutyl]-2,4,6-trihydroxy-1,3-benzene dicarboxaldehyde, in a combination with an acceptable carrier, for treating and/or preventing disorders or pathologies which are a result of a disorder of reuptake of the following neuromediators: dopamine, serotonin and/or noradrenaline, as well as to use of at least one compound selected from 5-[(1'R)-1'-[(1aS,3aS,4S,7R,7aR,7bS)-decahydro-7-hydroxy-1,1,3a,7-tetramethyl-1H-cyclopropa[A]naphthalen-4-yl]-3'-methylbutyl]-2,4,6-trihydroxy-1,3-benzene dicarboxaldehyde and 5-[(1'S)-1'-[(1aS,3aS,4S,7R,7aR,7bS)-decahydro-7-hydroxy-1,1,3a,7-tetramethyl-1H-cyclopropa[A]naphthalen-4-yl]-3'-methylbutyl]-2,4,6-trihydroxy-1,3-benzene dicarboxaldehyde to obtain a medicinal agent. n EFFECT: improved method. n 9 cl, 2 ex, 1 tbl |